Product Description
RGX-202-01 is a small molecule inhibitor of SLC6A8 that depletes intracellular PCr and ATP, resulting in apoptosis. In a completed Phase 1a study, RGX-202-01 monotherapy demonstrated objective anti-tumor activity in the relapsed/refractory KRAS-mut CRC setting without dose-limiting toxicity. (Sourced from: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3579)
Mechanisms of Action: SLC6A8 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inspirna
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Spain, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Acute Respiratory Distress Syndrome|Colorectal Cancer
Phase 1: Digestive System Cancer|Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RGX-202-002 | P2 |
Recruiting |
Colorectal Cancer |
2026-08-01 |
57% |
| RGX-202-002 | P2 |
Recruiting |
Acute Respiratory Distress Syndrome|Colorectal Cancer |
2026-02-26 |
|
| RGX-202-001 | P1 |
Recruiting |
Colorectal Cancer|Gastrointestinal Cancer|Digestive System Cancer |
2024-12-31 |
44% |